Download PDF
Z Gastroenterol 2018; 56(08): 994-997
DOI: 10.1055/a-0656-6055
Mitteilungen der DGVS
© Georg Thieme Verlag KG Stuttgart · New York

Stellungnahme zur vorläufigen Bewertung des IQWiG zum Nutzen eines Screenings auf Hepatitis C

Further Information

Publication History

Publication Date:
13 August 2018 (online)

Also available at
    Permissions and Reprints

Die Stellungnahme wurde verfasst von der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) e. V., gemeinsam mit

  • der Deutschen Gesellschaft für Infektiologie e. V. (DGI),

  • der Deutschen Gesellschaft für Innere Medizin e. V. (DGIM),

  • der Deutschen Leberhilfe,

  • der Deutschen Leberstiftung (DLS),

  • der Gesellschaft für Virologie (GfV) sowie

  • dem Robert Koch-Institut (RKI)

 

  • Literatur

  • 1 Groessl EJ, Weingart KR, Kaplan RM. et al. Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans. J Gen Intern Med 2008; 23: 1959-1965
    CrossrefPubMedGoogle Scholar
  • 2 Spiegel BM, Younossi ZM, Hays RD. et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800
    CrossrefPubMedGoogle Scholar
  • 3 Teixeira MC, Ribeiro MdeF, Gayotto LC. et al. Worse quality of life in volunteer blood donors with hepatitis C. Transfusion 2006; 46: 278-283
    CrossrefPubMedGoogle Scholar
  • 4 Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999; 29: 264-270
    CrossrefPubMedGoogle Scholar
  • 5 Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat 2009; 16: 605-611
    CrossrefPubMedGoogle Scholar
  • 6 McHutchison JG, Ware Jr JE, Bayliss MS. et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-147
    CrossrefPubMedGoogle Scholar
  • 7 Pojoga C, Dumitrascu DL, Pascu O. et al. The effect of interferon alpha plus ribavirin on health-related quality of life in chronic C hepatitis. The Romanian experience. J Gastrointestin Liver Dis 2006; 15: 31-35
    PubMedGoogle Scholar
  • 8 Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis 2015; 15: 19
    CrossrefPubMedGoogle Scholar
  • 9 Ware Jr JE, Bayliss MS, Mannocchia M. et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology 1999; 30: 550-555
    CrossrefPubMedGoogle Scholar
  • 10 Younossi ZM, Stepanova M, Afdhal N. et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015; 63: 337-345
    CrossrefPubMedGoogle Scholar
  • 11 Younossi DZM. Abstract 64. Significant and Sustained Improvement of Health-Related Quality of Life (HRQL) Scores in Patients with Hepatitis C (HCV) and Sustained Virologic Response (SVR). AASLD The Liver Meeting. Washington DC: 2017
    PubMedGoogle Scholar
  • 12 Younossi DZM. Abstract 737: Health-Related Quality of Life (HRQL) in East Asian Patients with Hepatitis C Virus (HCV) Infection: The Impact of Treatment and Sustained Virologic Response (SVR). AASLD The Liver Meeting 2017. Washington DC: 2017
    PubMedGoogle Scholar
  • 13 Mitchell DR. Abstract 1542: Patient-Reported Quality of Life Improves After Treatment of Hepatitis C with Direct-Acting Anti-Virals: A Real-World Experience. AASLD The Liver Meeting 2017. Washington DC: 2017
    PubMedGoogle Scholar
  • 14 Spencer FA, Iorio A, You J. et al. Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ 2012; 345: e7401
    CrossrefPubMedGoogle Scholar
  • 15 Iorio A, Spencer FA, Falavigna M. et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. British Medical Journal 2015; 350
    PubMedGoogle Scholar
  • 16 Bremer V, Cai W, Gassowski M. et al. Drogen und chronische Infektionskrankheiten in Deutschland – DRUCK-Studie: Robert Koch-Institut. 2016
    PubMedGoogle Scholar
  • 17 Wenz B, Nielsen S, Gassowski M. et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011–14). BMC Public Health 2016; 16: 927
    CrossrefPubMedGoogle Scholar
  • 18 Robert Koch-Institut. Hepatitis C – GBE Themenheft. Gesundheitsberichterstattung des Bundes. 2016 36. GBE
    PubMedGoogle Scholar
  • 19 Sarrazin CZT, Berg T, Neumann U. et al. Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. Zeitschrift für Gastroenterologie 2017; 56
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Bundesministerium_für_Gesundheit, Bundesministerium_für_wirtschaftliche_Zusammenarbeit_und_Entwicklung. Strategie zur Eindämmung von HIV, Hepatitis B und C und anderen sexuell übertragbaren Infektionen. BIS 2030 – Bedarfsorientiert · Integriert · Sektorübergreifend 2016
    PubMedGoogle Scholar
  • 21 WHO. Combating hepatitis B and C to reach elimination by 2013 – Advocacy brief. In: ed WHO Global Health Sector Strategy on Viral Hepatitis. 20. 2016
    Google Scholar
  • 22 Scott N, Olafsson S, Gottfreethsson M. et al. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020. J Hepatol 2018; 68: 932-939
    CrossrefPubMedGoogle Scholar
  • 23 Dore GJ, Hajarizadeh B. Elimination of Hepatitis C Virus in Australia: Laying the Foundation. Infect Dis Clin North Am 2018; 32: 269-279
    CrossrefPubMedGoogle Scholar
  • 24 Papatheodoridis GV, Hatzakis A, Cholongitas E. et al. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat 2018; 25 (Suppl. 01) 6-17
    PubMedGoogle Scholar
  • 25 Lazarus JV, Wiktor S, Colombo M. et al. Micro-elimination – A path to global elimination of hepatitis C. J Hepatol 2017; 67: 665-666
    CrossrefPubMedGoogle Scholar
  • 26 Cousien A, Tran VC, Deuffic-Burban S. et al. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France. J Viral Hepat 2018
    PubMedGoogle Scholar
  • 27 Vermehren J, Schlosser B, Domke D. et al. High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: a prospective screening analysis of 28809 patients. PLoS One 2012; 7: e41206
    CrossrefPubMedGoogle Scholar
  • 28 Wolffram I, Petroff D, Batz O. et al. Prevalence of elevated ALT values, HBsAg, and anti-HCV in the primary care setting and evaluation of guideline defined hepatitis risk scenarios. J Hepatol 2015; 62: 1256-1264
    CrossrefPubMedGoogle Scholar
  • 29 Fraser H, Martin NK, Brummer-Korvenkontio H. et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol 2018; 68: 402-411
    CrossrefPubMedGoogle Scholar
  • 30 Islam N, Krajden M, Shoveller J. et al. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. The Lancet Gastroenterology & Hepatology 2017; 2: 200-210
    CrossrefPubMedGoogle Scholar
  • 31 Ingiliz P, Martin TC, Rodger A. et al. HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe. J Hepatol 2017; 66: 282-287
    CrossrefPubMedGoogle Scholar
  • 32 Midgard H, Bjoro B, Maeland A. et al. Hepatitis C reinfection after sustained virological response. J Hepatol 2016; 64: 1020-1026
    CrossrefPubMedGoogle Scholar
  • 33 Tang W, Chen W, Amini A. et al. Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature. BMC Infect Dis 2017; 17: 695
    CrossrefPubMedGoogle Scholar
  • 34 WHO. WHO Guidelines on Hepatitis B and C Testing – WHO Guidelines Approved by the Guidelines Review Committee. In: ed WHO G. 2017
    Google Scholar
  • 35 Easterbrook PJ, Roberts T, Sands A. et al. Diagnosis of viral hepatitis. Curr Opin HIV AIDS 2017; 12: 302-314
    CrossrefPubMedGoogle Scholar
  • 36 Zuure FR, Urbanus AT, Langendam MW. et al. Outcomes of hepatitis C screening programs targeted at risk groups hidden in the general population: a systematic review. BMC Public Health 2014; 14: 66
    CrossrefPubMedGoogle Scholar
  • 37 Adinolfi LE, Nevola R, Lus G. et al. Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview. World J Gastroenterol 2015; 21: 2269-2280
    CrossrefPubMedGoogle Scholar
  • 38 Fletcher NF, McKeating JA. Hepatitis C virus and the brain. J Viral Hepat 2012; 19: 301-306
    CrossrefPubMedGoogle Scholar
  • 39 Honer ZuSiederdissen C, Buggisch P, Boker K. et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J 2018; 6: 213-224
    PubMedGoogle Scholar
  • 40 Mangia A, Piazzolla V, Losappio R. et al. High SVR rates in patients with and without cirrhosis treated in real life with Sofosbuvir/Velpatasvir (SOF/VEL) combination for 12 weeks without Ribavirin (RBV) (THU-323). Journal of Hepatology Supplement 1 – Abstracts of The International Liver Congress™ 2018 – 53rd annual meeting of the European Association for the Study of the Liver (April 11 – 15, 2018, Paris, France) 2018; 68: S273
    PubMedGoogle Scholar
  • 41 Vermehren J, Dietz J, Peiffer K-H. et al. Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/velpatasvir/voxilaprevir: results from the Frankfurt Resistance Database (THU-347). Journal of Hepatology 2018; 68 (Suppl. 01) S285
    PubMedGoogle Scholar
  • 42 Berg T, Naumann U, Stoehr A. et al. First real-world data on safety and effectiveness of glecaprevir/pibrentasvir for the treatment of patients with chronic hepatitis C virus infection: Data from the German Hepatitis C-Registry (GS-007). Journal of Hepatology 2018; 68 (Suppl. 01) S528
    PubMedGoogle Scholar
  • 43 Hansen JF, Hallager S, Øvrehus A. et al. Late Presentation for Care Among Patients With Chronic Hepatitis C: Prevalence and Risk Factors. Open Forum Infectious Diseases 2018; 5: ofx257-ofx257
    PubMedGoogle Scholar
  • 44 van der Meer AJ, Veldt BJ, Feld JJ. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593
    CrossrefPubMedGoogle Scholar
  • 45 van der Meer AJ. Achieving sustained virological response: whatʼs the impact on further hepatitis C virus-related disease?. Expert Rev Gastroenterol Hepatol 2015; 9: 559-566
    CrossrefPubMedGoogle Scholar
  • 46 van der Meer AJ, Maan R, Veldt BJ. et al. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016; 31: 1168-1176
    CrossrefPubMedGoogle Scholar
  • 47 Chen YiMei SLG, Thompson AJ, Christensen B. et al. Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection. PLoS One 2017; 12: e0185609
    CrossrefPubMedGoogle Scholar
  • 48 Freeman AJ, Law MG, Kaldor JM. et al. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 285-293
    CrossrefPubMedGoogle Scholar